AntriaBio is a clinical-stage biopharmaceutical growth company focused on developing drug therapies for patients with diabetes and metabolic diseases. Its lead product candidate, AB101, is an injectable once-weekly basal insulin intended for type 1 and type 2 diabetes that targets a greater than $10 billion market currently served by once-daily basal insulin. The company filed an IND for AB101 that became effective without hold on July 1, 2017, and is proceeding with a planned first-in-human Phase 1 clinical trial, anticipating dosing the first patient prior to the end of the month. AntriaBio intends to use proceeds from its recent financing for general corporate purposes including the Phase 1 study of AB101 and advancing emerging pipeline candidates. The company announced a $13 million close of a private placement and noted the securities sold in the financing have not been registered under the U.S. Securities Act of 1933. AntriaBio develops novel extended‑release therapies by combining proprietary formulation and microsphere manufacturing capabilities with well‑known molecules. Its lead product candidate, AB101, is an injectable once‑weekly basal insulin for patients with type 1 and type 2 diabetes. The company positions AB101 to address an approximately $11 billion global basal insulin market where the current standard is a once‑daily basal insulin injection. AntriaBio plans to use financing proceeds for general corporate purposes including preparation for Phase 1 clinical studies for AB101 and to advance other potential long‑acting product candidates in its pipeline. Since its inception in 2013 the company has raised roughly $35 million through equity financings. The company is based in Louisville, Colorado. AntriaBio develops novel extended‑release therapies using proprietary formulation and manufacturing paired with known molecules. Its lead candidate, AB101, is a basal insulin designed for potential once‑weekly dosing for patients with type 1 and type 2 diabetes. The company will use proceeds from the $7M private placement for general corporate purposes, including production of cGMP material and initiation of Phase 1 clinical studies for AB101. AntriaBio said fundraising efforts in 2014 were instrumental in advancing the AB101 clinical program and cited the candidate’s potential to transform the $10 billion basal insulin market. The securities sold in the financing have not been registered under the U.S. Securities Act and may not be offered or sold in the U.S. absent registration or an applicable exemption. As part of the financing, the company agreed to file a resale registration statement on Form S-1 within 90 days to register resale of the shares issued or issuable in connection with the financing. AntriaBio, based in Menlo Park, CA, is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Its lead product candidate, AB101, is a proprietary microsphere insulin formulation designed for once-weekly administration. The company says AB101 has the potential to transform the more than $10 billion a year basal insulin market. AntriaBio's development strategy combines FDA-approved pharmaceutical agents with its proprietary delivery technology. Proceeds from the announced financing will be used for general corporate purposes, including costs associated with AB101's clinical development program. Management stated the financing leaves the company with a "healthy balance sheet." AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Its lead product candidate, AB101, is a proprietary microsphere formulation of insulin intended to be administered once per week for Type 1 and Type 2 diabetes. The company combines FDA-approved pharmaceutical agents with proprietary delivery technology and is targeting the more than $8 billion a year basal insulin market. AntriaBio plans to begin clinical studies for AB101 and is raising additional funds in a private placement in Q1 2014 to support that development. Bridge financing proceeds will be used for general corporate purposes, including establishing a cGMP manufacturing facility in the greater Denver, Colorado area. Nevan Elam serves as Chairman and CEO. The company received net cash proceeds of $2.7 million from the bridge financing, excluding placement agent compensation, transaction costs, fees and expenses.

Total raised

$10M

Funding rounds

5

Latest round

Equity

Latest activity

Apr 2014